Certain Antidepressants May Increase Risk of Impulse Control Disorder in Parkinson ’s Patients
Taking serotonergic antidepressants such as serotonin and norepinephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) may increase the risk of patients with Parkinson ’s disease developing impulse control disorder, astudy inThe American Journal of Geriatric Psychiatry has found.Impulse control disorders —which include a range of behaviors such as excessive gambling, spending, cleaning, and eating—are one of “the most challenging psychiatric syndromes” affecting people living with Parkinson’s disease, wrote Christopher B. Morrow, M.D., M.H.S., of the Johns Hopkins University Sch...
Source: Psychiatr News - January 5, 2024 Category: Psychiatry Tags: antidepressants gambling impulse control disorders Parkinson ' s disease SNRIs spending SSRIs The American Journal of Geriatric Psychiatry Source Type: research
No link between popular weight loss drugs and suicidal thoughts, health records suggest
A wildly popular class of obesity and diabetes drugs isn’t associated with suicidal thinking, a new report suggests—even as drug regulators in the United States and Europe probe a potential connection. The government-funded study, published today, was initiated in response to case reports that the drugs—which are called glucagon-like peptide-1 (GLP-1) agonists and include Ozempic for diabetes and Wegovy for weight loss—might increase suicidal thinking. Drawing on more than 1 million U.S. health records, the new study finds no such worrisome link, and even suggests the drugs may reduce thoughts of suicide. However, ...
Source: Science of Aging Knowledge Environment - January 5, 2024 Category: Geriatrics Source Type: research
Alprazolam/Bupropion
(Source: Reactions Weekly)
Source: Reactions Weekly - January 1, 2024 Category: Drugs & Pharmacology Source Type: research
Bicarbonate/Bupropion
(Source: Reactions Weekly)
Source: Reactions Weekly - January 1, 2024 Category: Drugs & Pharmacology Source Type: research
Competitive inhibition of nicotine acetylcholine receptors using microneedles of nicotine and varenicline for smoking withdrawal therapy
Eur J Pharm Biopharm. 2023 Dec 28:114171. doi: 10.1016/j.ejpb.2023.114171. Online ahead of print.ABSTRACTCurrent strategies for smoking withdrawal conditions involve monotherapy of nicotine and combinational therapy of nicotine with varenicline or bupropion as per the CDC and FDA. The available dosage forms for nicotine are patches, gums, inhalers and nasal sprays, bupropion and varenicline are available in tablet form. This research work focused on developing a microneedle delivery system to deliver combination drug for overcoming the obstacles encountered by oral route of administration of varenicline such as severe side...
Source: European Journal of Pharmaceutics and Biopharmaceutics - December 30, 2023 Category: Drugs & Pharmacology Authors: Ashwini Wani Bala Prabhakar Pravin Shende Source Type: research
Effects of different combined behavioral and pharmacological interventions on smoking cessation: a network meta-analysis of 103 randomized controlled trials
ConclusionsAmong combined interventions for smoking cessation, Varenicline + CBT, NRT + CBT + Financial incentive, and Bupropion + CBT demonstrate the highest levels of success. CBT, FI, and Varenicline are potential intervention components that may possess greater effectiveness. (Source: Journal of Public Health)
Source: Journal of Public Health - December 21, 2023 Category: Health Management Source Type: research
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: Lorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT.CLINICALTRIALS: gov: NCT01970865.PMID:38079095 | DOI:10.1007/s40262-023-01309-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Joseph Chen Alessandra Bearz Dong-Wan Kim Hirva Mamdani Jessica Bauman Rita Chiari Sai-Hong Ignatius Ou Benjamin J Solomon Ross A Soo Enriqueta Felip Alice T Shaw Holger Thurm Jill S Clancy Kimberly Lee Melissa O'Gorman Cherie Tanski Yazdi K Pithavala Source Type: research
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
CONCLUSIONS: Lorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT.CLINICALTRIALS: gov: NCT01970865.PMID:38079095 | DOI:10.1007/s40262-023-01309-4 (Source: Clinical Lung Cancer)
Source: Clinical Lung Cancer - December 11, 2023 Category: Cancer & Oncology Authors: Joseph Chen Alessandra Bearz Dong-Wan Kim Hirva Mamdani Jessica Bauman Rita Chiari Sai-Hong Ignatius Ou Benjamin J Solomon Ross A Soo Enriqueta Felip Alice T Shaw Holger Thurm Jill S Clancy Kimberly Lee Melissa O'Gorman Cherie Tanski Yazdi K Pithavala Source Type: research
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer
ConclusionsLorlatinib is a net moderate inducer of P-gp and a weak inducer of CYP2B6, CYP2C9, and UGT after steady state is achieved with daily dosing. Medications that are P-gp substrates with a narrow therapeutic window should be avoided in patients taking lorlatinib; no dose modifications are needed with substrates of CYP2B6, CYP2C9, or UGT.ClinicalTrials.gov: NCT01970865. (Source: Clinical Pharmacokinetics)
Source: Clinical Pharmacokinetics - December 11, 2023 Category: Drugs & Pharmacology Source Type: research
Early- and later-stage persistence with antiobesity medications: A retrospective cohort study
CONCLUSIONS: Later-stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.PMID:38053443 | DOI:10.1002/oby.23952 (Source: Obesity)
Source: Obesity - December 6, 2023 Category: Eating Disorders & Weight Management Authors: Hamlet Gasoyan Elizabeth R Pfoh Rebecca Schulte Phuc Le Michael B Rothberg Source Type: research
"Poor Person's Cocaine": Bupropion Insufflation Inducing Manic Symptoms and Its Abuse Potential in Dual Diagnosis Patients
Prim Care Companion CNS Disord. 2023 Nov 21;25(6):23cr03557. doi: 10.4088/PCC.23cr03557.NO ABSTRACTPMID:38055868 | DOI:10.4088/PCC.23cr03557 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - December 6, 2023 Category: Primary Care Authors: Greg Noe Samantha Ongchuan Martin Kaushal Shah Sahil Munjal Source Type: research
"Poor Person's Cocaine": Bupropion Insufflation Inducing Manic Symptoms and Its Abuse Potential in Dual Diagnosis Patients
Prim Care Companion CNS Disord. 2023 Nov 21;25(6):23cr03557. doi: 10.4088/PCC.23cr03557.NO ABSTRACTPMID:38055868 | DOI:10.4088/PCC.23cr03557 (Source: Primary Care)
Source: Primary Care - December 6, 2023 Category: Primary Care Authors: Greg Noe Samantha Ongchuan Martin Kaushal Shah Sahil Munjal Source Type: research
Early- and later-stage persistence with antiobesity medications: A retrospective cohort study
CONCLUSIONS: Later-stage persistence with AOM varies considerably based on the drug and the weight loss at 6 months.PMID:38053443 | DOI:10.1002/oby.23952 (Source: Obesity)
Source: Obesity - December 6, 2023 Category: Eating Disorders & Weight Management Authors: Hamlet Gasoyan Elizabeth R Pfoh Rebecca Schulte Phuc Le Michael B Rothberg Source Type: research
"Poor Person's Cocaine": Bupropion Insufflation Inducing Manic Symptoms and Its Abuse Potential in Dual Diagnosis Patients
Prim Care Companion CNS Disord. 2023 Nov 21;25(6):23cr03557. doi: 10.4088/PCC.23cr03557.NO ABSTRACTPMID:38055868 | DOI:10.4088/PCC.23cr03557 (Source: The Primary Care Companion for CNS Disorders)
Source: The Primary Care Companion for CNS Disorders - December 6, 2023 Category: Primary Care Authors: Greg Noe Samantha Ongchuan Martin Kaushal Shah Sahil Munjal Source Type: research
